Novo Nordisk AS (MEX:NVON) General and Admin. Expense: MXN16,818 Mil (TTM As of Mar. 2026)


MEX:NVON Novo Nordisk AS MEX:NVON
76 GF Score
Price MXN831.50
GF Value MXN2,387.52
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Novo Nordisk AS General and Admin. Expense?

Novo Nordisk AS MEX:NVON -0.60% 76 General and Admin. Expense is MXN16,818 Mil as of Mar. 2026. GuruFocus rates MEX:NVON with a GF Score™ of 76/100 and a GF Value™ of MXN2,387.52 (Significantly Undervalued). The stock has 4 warning signs investors should review.

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. Novo Nordisk AS's General and Admin. Expense for the three months ended in Mar. 2026 was MXN3,180 Mil. Its General and Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 was MXN16,818 Mil.

Novo Nordisk AS General and Admin. Expense Related Terms

Novo Nordisk AS General and Admin. Expense Historical Data

* Premium members only.

The historical data trend for Novo Nordisk AS's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novo Nordisk AS General and Admin. Expense Chart

Novo Nordisk AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
General and Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12,624.48 12,400.67 12,057.41 15,449.75 16,850.00

Novo Nordisk AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
General and Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,617.61 3,831.05 5,434.89 4,372.70 3,179.63
MEX:NVON
76GF Score
Novo Nordisk AS MEX:NVON
General and Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novo Nordisk AS General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.

General and Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN16,818 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a General and Admin. Expense of MXN16,818 Mil mean?
Novo Nordisk AS (MEX:NVON) has a General and Admin. Expense of MXN16,818 Mil as of Mar. 2026. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Novo Nordisk AS and its competitors.
Is Novo Nordisk AS's General and Admin. Expense too high?
Novo Nordisk AS's current General and Admin. Expense is MXN16,818 Mil. Overall, Novo Nordisk AS has a GF Score™ of 76/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Novo Nordisk AS's General and Admin. Expense compare to LLY and JNJ?
Novo Nordisk AS's General and Admin. Expense of MXN16,818 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good General and Admin. Expense for a Drug Manufacturers company?
A good General and Admin. Expense depends on the Drug Manufacturers industry context. However, General and Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high General and Admin. Expense mean?
A high General and Admin. Expense can signal that a stock is expensive relative to its fundamentals. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Novo Nordisk AS and its competitors. Novo Nordisk AS's current General and Admin. Expense is MXN16,818 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novo Nordisk AS stock overvalued right now?
Based on GuruFocus' analysis, Novo Nordisk AS (MEX:NVON) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN2,387.52, compared to a current price of MXN831.50 — trading 65.2% below its estimated fair value. The current General and Admin. Expense is MXN16,818 Mil. Novo Nordisk AS's overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is General and Admin. Expense calculated?
General and Admin. Expense is calculated from a company's financial statements. For Novo Nordisk AS (MEX:NVON), the current General and Admin. Expense is MXN16,818 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novo Nordisk AS (MEX:NVON) Overvalued in 2026?

Based on GuruFocus' analysis, Novo Nordisk AS stock appears to be undervalued. The current stock price of MXN831.50 is trading 65.2% below its estimated GF Value™ of MXN2,387.52. GuruFocus considers Novo Nordisk AS to be Significantly Undervalued.

Key valuation signals for MEX:NVON:

  • General and Admin. Expense: MXN16,818 Mil
  • GF Value™: MXN2,387.52 vs. price of MXN831.50 (65.2% below fair value)
  • GF Score™: 76/100 with 4 warning signs

No single metric tells the full story. See the MEX:NVON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novo Nordisk AS Business Description

Address Novo Alle 1, Bagsvaerd, DNK, 2880
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
76GF Score

Get the complete analysis for MEX:NVON

General and Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN831.50
Price
MXN2,387.52
GF Value